Therapy Areas: Vaccines
Sinovac's COVID-19 vaccine approved in Brazil for young children
14 July 2022 -

Chinese biopharmaceutical company Sinovac Biotech Ltd (NASDAQ:SVA) announced on Thursday that its COVID-19 vaccine, CoronaVac, has been approved in Brazil for use in children aged 3 to 5 years.

Brazilian health regulator Anvisa stated that these children will receive the same dose that is already applied to minors aged 6 to 17 years and adults and there is no restriction on the application for immunosuppressed children aged 3 to 5 years.

The approval was based on analysis of all available data on the vaccine and its use in children, including research data from Chile, where the vaccine is already used in this age group.

CoronaVac has been authorised for emergency use for adults in Brazil since 17 January 2021, and in children and adolescents 6 to 17 years of age from 20 January 2022.

The vaccine is authorised for emergency use for minors in 14 countries and regions, including Chile, Colombia, Ecuador, Brazil.